Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Symeonidis

Showing results (541-550 of 578) with videos related to

Pageof 58
Sort By:
British Journal of Haematology|August 31, 2020
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomesPanagiotis T Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, et al.
Frontiers in Medicine|October 30, 2023
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter dataEleni Gavriilaki, Emmanuel Nikolousis, Eudoxia-Evaggelia Koravou, et al.
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
Annals of Hematology|May 15, 2018
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survivalEirini Katodritou, Marie-Christine Kyrtsonis, Sosana Delimpasi, et al.
Journal of Hematology|November 4, 2024
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World ExperienceCiprian Jitaru, Argyris Symeonidis, Sorina Badelita, et al.
American Journal of Hematology|April 24, 2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patientsEirini Katodritou, Evangelos Terpos, Argiris S Symeonidis, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Annals of Hematology|June 27, 2018
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survivalEirini Katodritou, Marie-Christine Kyrtsonis, Sosana Delimpasi, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Pageof 58

Showing results (541-550 of 578) with videos related to

Sort By:
Pageof 58
British Journal of Haematology|August 31, 2020
The effect of 5-azacytidine treatment delays and dose reductions on the prognosis of patients with myelodysplastic syndrome: how to optimize treatment results and outcomesPanagiotis T Diamantopoulos, Argiris Symeonidis, Vasiliki Pappa, et al.
Frontiers in Medicine|October 30, 2023
Caplacizumab for immune thrombotic thrombocytopenic purpura: real-world multicenter dataEleni Gavriilaki, Emmanuel Nikolousis, Eudoxia-Evaggelia Koravou, et al.
Leukemia|March 25, 2018
Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet studyReinhard Stauder, Ge Yu, Karin A Koinig, et al.
Annals of Hematology|May 15, 2018
Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survivalEirini Katodritou, Marie-Christine Kyrtsonis, Sosana Delimpasi, et al.
Journal of Hematology|November 4, 2024
Siltuximab in Idiopathic Multicentric Castleman Disease: Real-World ExperienceCiprian Jitaru, Argyris Symeonidis, Sorina Badelita, et al.
American Journal of Hematology|April 24, 2014
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: a report of the Greek myeloma study group in 97 patientsEirini Katodritou, Evangelos Terpos, Argiris S Symeonidis, et al.
Blood|September 30, 2022
The proto-oncogene TCL1A deregulates cell cycle and genomic stability in CLLJohanna Stachelscheid, Qu Jiang, Christoph Aszyk, et al.
British Journal of Haematology|April 25, 2015
Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registryLouise de Swart, Alex Smith, Thomas W Johnston, et al.
Annals of Hematology|June 27, 2018
Correction to: Real-world data on Len/Dex combination at second-line therapy of multiple myeloma: treatment at biochemical relapse is a significant prognostic factor for progression-free survivalEirini Katodritou, Marie-Christine Kyrtsonis, Sosana Delimpasi, et al.
The Lancet. Haematology|January 15, 2022
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 studyFredrik H Schjesvold, Meletios-Athanasios Dimopoulos, Sosana Delimpasi, et al.
Pageof 58